Why You Might Still Feel Hungry on Wegovy 2.4mg

What the STEP 1 trial actually found about appetite at maintenance dose

The STEP 1 trial, published in the New England Journal of Medicine, enrolled over 1,900 adults with obesity and tracked them for 68 weeks on semaglutide 2.4mg alongside lifestyle support. Average weight loss across the group reached around 15%. That headline figure, though impressive, conceals a wide spread: some participants lost significantly more, others far less. Appetite suppression showed the same pattern. Semaglutide works by activating GLP-1 receptors in the gut and brain, slowing how quickly the stomach empties and helping you feel full sooner and for longer. But receptor sensitivity, gut motility and how the brain processes fullness signals are not uniform across people. If you are curious about what to expect when you first reach the maintenance level, our page on Wegovy 2.4mg covers the dose in detail, including how it compares to earlier steps in the schedule. If hunger feels persistent or even stronger at 2.4mg than it did at 1.7mg, that is not unusual and it is not a sign you have done something wrong.

Tolerance is also a factor the evidence supports. After months at the same dose, some people notice the appetite-dampening effect softens. This is different from the medicine stopping work, it often reflects physiological adaptation rather than true loss of efficacy. The NHS patient information for semaglutide notes that side effects and effects on appetite can change over time at a steady dose, which is part of why ongoing clinical review matters.

Diet composition and meal timing matter more than many patients realise at this dose

At lower doses, even a modest improvement in appetite is often enough to drive meaningful calorie reduction. At 2.4mg, patients who are still eating frequently processed foods, drinking calories, or skipping protein find that hunger signals break through more easily. This is not a character flaw; it is physiology. Semaglutide's effect on the stomach empties more slowly when meals are high in fat and refined carbohydrate, which can paradoxically cause discomfort rather than fullness in some people. Protein and fibre, by contrast, interact well with slowed gastric emptying to extend satiety.

Meal timing is another practical consideration. Some people on 2.4mg find hunger spikes in the 24 to 48 hours before their next weekly injection, a pattern sometimes called the "end-of-week" effect. Keeping a simple food and hunger diary for two weeks can help you and your prescriber identify whether this is happening. If you are approaching your injection day and appetite is reliably surging, that is worth mentioning at your next clinical review. Our prescribers hear this question most weeks; it has a clinical answer, not just a lifestyle one. You can explore the full Wegovy dose schedule to understand where 2.4mg sits in the titration pathway and why it is not automatically the end of the road.

When persistent hunger at 2.4mg is a signal to act on

There is a meaningful difference between mild, intermittent hunger (which is normal and manageable) and hunger that is making it impossible to maintain a calorie deficit despite months at maintenance dose. The latter deserves a proper clinical conversation, not self-management. Your prescriber can review several things: whether the titration schedule was paced correctly, whether there are other medicines or health conditions affecting appetite regulation, and whether continuing at 2.4mg is the right plan. It is also worth knowing that breakthrough hunger at the penultimate dose is well documented, and our page on being hungry on Wegovy 1.7 explains why that step can feel particularly difficult for some people.

From a regulatory standpoint, NICE guidance notes that if weight loss of less than 5% is achieved after six months at the highest tolerated dose, continuing treatment should be reconsidered, see NICE technology appraisal TA875 for the published criteria. That threshold is a clinical decision point, not a verdict on you personally. Some people who remain persistently hungry at 2.4mg are also candidates for a conversation about tirzepatide, which works across two receptor pathways rather than one; the trial data comparing the two medicines showed greater average weight reduction with tirzepatide. Our treatment overview page covers both options in plain terms.

One practical note: if your prescription falls due during a bank holiday or you are away in August, arrange your repeat order a few days early. Missing even a single injection week can affect appetite control and make the return-to-injection week harder. It is a small logistical detail that is easy to forget but genuinely matters for continuity.

What to do next if hunger is ongoing at this dose

First, rule out the straightforward causes: low protein at meals, insufficient sleep, high stress, or eating too quickly. These genuinely blunt the medicine's effect and are addressable without changing your prescription. Second, if hunger is affecting your progress meaningfully, document it (when it peaks, what triggers it, how long it lasts) and bring that to your prescriber. A clinical review is the appropriate setting for this conversation, not a forum or a search engine.

At nume, every repeat order is reviewed individually by a GPhC-registered prescriber before dispatch, there are no automatic refills. That means there is always a point in the process where a question like this can be raised and answered properly. For background on the 2.4mg pen itself, including how it differs from earlier dose pens in the schedule, the Wegovy 2.4mg pen page has more detail. If you are finding hunger particularly sharp during the first few weeks at this dose, the experience described on our page about persistent hunger at 2.4mg may also be useful. Patients who noticed strong hunger right from the beginning of treatment, including at the starting dose, may find our page on still feeling hungry on Wegovy 0.25 a helpful point of comparison for how appetite can evolve across the full titration.

If you have not yet started treatment or are considering a switch, checking your eligibility with our prescribers is the first step. The consultation is free, and the clinical review happens the same day.